C4 Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
C4 Therapeutics, Inc. (CCCC) reported Impairment of Long-Lived Assets Held-for-use of $10.73 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-11-06
- C4 Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $10.73M.
- C4 Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 9 month |
|---|---|---|
| 2025-09-30 | $10.73M 10-Q · filed 2025-11-06 | $10.73M 10-Q · filed 2025-11-06 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |